WHAT IS CLAIMED IS:

1. A compound of Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, a prodrug, a stereoisomer, an N-oxide, or a pharmaceutically acceptable salt thereof,



(I), or



(Ia)

wherein each R^1 is independently H, F, Cl, Br, I, nitro, trifluoromethyl or cyano;

each R^2 is independently methyl or ethyl;

each R^3 is independently thiazolyl, oxazolyl or imidazolyl; wherein optionally each of thiazolyl, oxazolyl and imidazolyl is independently unsubstituted or substituted with methyl or cyclopropyl;

each Z is independently O or S;

each R^4 is independently $-(CR^5R^{5a})_t-C(=O)-OH$;

each R^{4a} is independently H, methyl or isopropyl;

each R^5 and R^{5a} is independently H, F or methyl, or $R^5$and R^{5a}, together with the carbon atom to which they are attached, form cyclopropyl or -C(=O);

wherein each n is independently 1, 2 or 3;

each m is independently 0, 1 or 2; and

t is 1, 2, 3 or 4.

2. The compound according to claim 1, wherein R^3 is



3. The compound according to claim 1 having one of the following structures:


(1),


(2),


(3),


(4),


(5),


(6),


(7),


(8),


(9),


(10),


(11),


(12),


(13)，


(14)，


(15)，


(16)，


(17)，


(18)，


(19)，


(20)，


(21)，


(22)，


(23)，


(24)，


(25)，


(26)，


(27)，


(28),

(29),

(30),

(31),

(32),

(33),

(34),

(35),

(36),

(37),

(38),

(39),

(40),

(41),

(42),



(43)



(44)



(45)



(46)



(47)



(48)



(49)



(50)



(51)



(52)



(53)



(54)



(55)



(56)



(57)


(58),

(59),

(60),

(61),

(62),

(63),

(64),

(65),

(66),

(67),

(68),

(69),

(70),

(71),

(72),


(73),

(74),

(75),

(76),

(77),

(78),

(79),

(80),

(81),

(82),

(83),

(84),

(85),

(86),

(87),


(88),


(89),


(90),


(91),


(92),


(93),


(94),


(95),


(96),


(97),


(98),


(99),


(100),


(101),


(102),


(103)，


(104)，


(105)，


(106)，


(107)，


(108)，


(109)，


(110)，


(111)，


(112)，


(113)，


(114)，


(115)，


(116)，


(117)，


(118),


(119),


(120),


(121),


(122),


(123),


(124),


(125),


(126),


(127),


(128),


(129),


(130),


(131),


(132),


(133)，


(134)，


(135)，


(136)，


(137)，


(138)，


(139)，


(140)，


(141)，


(142)，


(143)，


(144)，


(145)，


(146)，


(147)，


(148)


(149)


(150)


(151)


(152)


(153)


(154)


(155)


(156)


(157)


(158)


(159)


(160)


(161)


(162)


(163)


(164)


(165)


(166)


(167)


(168)


(169)


(170)


(171)


(172)


(173)


(174)


(175)


(176)


(177)


(178),

(179),

(180),

(181),

(182),

(183),

(184), or

(185),

or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, a prodrug, a stereoisomer, an N-oxide , or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising the compound according to any one of claims 1-3.

5. The pharmaceutical composition according to claim 4 further comprises a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

6. The pharmaceutical composition according to claim 4 further comprises an anti-HBV agent.

7. The pharmaceutical composition according to claim 6, wherein the anti-HBV agent is an HBV polymerase inhibitor, immunomodulator or interferon.

8. The pharmaceutical composition according to claim 6, wherein the anti-HBV agent is

lamivudine, telbivudine, tenofovir, entecavir, adefovir dipivoxil, alfaferone, alloferon, celmoleukin, clevudine, emtricitabine, famciclovir, feron, hepatect CP, intefen, interferon α-1b, interferon α, interferon α-2a, interferon β-1a, interferon α-2, interleukin-2, mivotilate, nitazoxanide, peginterferon alfa-2a, ribavirin, roferon-A, sizofiran, euforavac, veldona, rintatolimod, phosphazid, heplisav, interferon α-2b, levamisole, or propagermanium.

9. Use of the compound according to any one of claims 1-3 or the pharmaceutical composition according to any one of claims 4-8 in the manufacture of a medicament for preventing, managing, treating or lessening an HBV disease in a patient.

10. The use according to claim 9, wherein the HBV disease is hepatitis B infection or a disease caused by hepatitis B infection.

11. The use according to claim 10, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.